ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26 th International AIDS Conference ...

HIV treatment has progressed significantly since the 1980s. ART enables viral suppression and prevents transmission, but HIV ...

Following in the footsteps of Gilead Sciences, Merck & Co. has signed voluntary licensing agreements to enable access to its ...

Merck enters new agreement with ADAP Crisis Task Force to improve access and care for people living with HIV: Rahway, New Jersey Wednesday, July 1, 2026, 14:00 Hrs [IST] Merck, kn ...

Merck has announced an early global access plan for Alimatravir, an experimental once-monthly pill being developed to prevent ...

On Tuesday, the White House Office of Science and Technology Policy (OSTP) released a report entitled “Science: A New Golden ...

Planning early for rapid, broad and sustainable access in LMICs : By initiating a multi-faceted access strategy while Phase 3 trials are ongoing and before enrollment is complete, Merck aims to make ...

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026: London ...

A research team has developed a multisite bridging-mediated lateral flow immunoassay (mbLFIA) that enables highly sensitive, ...

For the first time, Merck has granted generic manufacturers, including three African companies, permission to produce an ...

Week 48 results showed that the once-weekly single tablet regimen of ISL/LEN was noninferior to BIKTARVY in maintaining virologic suppression; no (0%) participants who switched to ISL/LEN had HIV-1 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV treatment and prevention will be presented at the 26th ...